Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Byeongjin | - |
dc.contributor.author | Kang, Hyejin | - |
dc.contributor.author | Lee, Wonhwa | - |
dc.contributor.author | Noh, Hyun Jin | - |
dc.contributor.author | Kim, You-Sun | - |
dc.contributor.author | Han, Min-Su | - |
dc.contributor.author | Baek, Moon-Chang | - |
dc.contributor.author | Kim, Jaehong | - |
dc.contributor.author | Bae, Jong-Sup | - |
dc.date.available | 2020-02-28T02:43:05Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016-04 | - |
dc.identifier.issn | 1976-6696 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8423 | - |
dc.description.abstract | A nucleosomal protein, high mobility group box 1 (HMGB1) is known to be a late mediator of sepsis. Dabrafenib is a B-Raf inhibitor and initially used for the treatment of metastatic melanoma therapy. Inhibition of HMGB1 and renewal of vascular integrity is appearing as an engaging therapeutic strategy in the administration of severe sepsis or septic shock. Here, we examined the effects of dabrafenib (DAB) on the modulation of HMGB1-mediated septic responses. DAB inhibited the release of HMGB1 and downregulated HMGB1-dependent inflammatory responses by enhancing the expressions of cell adhesion molecules (CAMs) in human endothelial cells. In addition, treatment with DAB inhibited the HMGB1 secretion by CLP and sepsis-related mortality and pulmonary injury. This study demonstrated that DAB could be alternative therapeutic options for sepsis or septic shock via the inhibition of the HMGB1 signaling pathway. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY | - |
dc.relation.isPartOf | BMB REPORTS | - |
dc.subject | MOBILITY GROUP BOX-1 | - |
dc.subject | ACTIVATED PROTEIN-C | - |
dc.subject | GLYCATION END-PRODUCTS | - |
dc.subject | ENDOTHELIAL-CELLS | - |
dc.subject | SEVERE SEPSIS | - |
dc.subject | DRUG DISCOVERY | - |
dc.subject | HMGB1 | - |
dc.subject | SHOCK | - |
dc.subject | RECEPTOR | - |
dc.title | Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000378131700005 | - |
dc.identifier.doi | 10.5483/BMBRep.2016.49.4.220 | - |
dc.identifier.bibliographicCitation | BMB REPORTS, v.49, no.4, pp.214 - 219 | - |
dc.identifier.kciid | ART002102268 | - |
dc.identifier.scopusid | 2-s2.0-84966670353 | - |
dc.citation.endPage | 219 | - |
dc.citation.startPage | 214 | - |
dc.citation.title | BMB REPORTS | - |
dc.citation.volume | 49 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Kim, Jaehong | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Barrier integrity | - |
dc.subject.keywordAuthor | Dabrafenib | - |
dc.subject.keywordAuthor | HMGB1 | - |
dc.subject.keywordAuthor | Sepsis | - |
dc.subject.keywordPlus | MOBILITY GROUP BOX-1 | - |
dc.subject.keywordPlus | ACTIVATED PROTEIN-C | - |
dc.subject.keywordPlus | GLYCATION END-PRODUCTS | - |
dc.subject.keywordPlus | ENDOTHELIAL-CELLS | - |
dc.subject.keywordPlus | SEVERE SEPSIS | - |
dc.subject.keywordPlus | DRUG DISCOVERY | - |
dc.subject.keywordPlus | HMGB1 | - |
dc.subject.keywordPlus | SHOCK | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.